Review of Helius Medical Technologies (NASDAQ:HSDT) and CONMED (NYSE:CNMD)

CONMED (NYSE: CNMD – Get Rating) and Helius Medical Technologies (NASDAQ: HSDT – Get Rating) are both medical companies, but which is the better company? We’ll compare the two companies based on their dividend strength, valuation, institutional ownership, earnings, profitability, risk, and analyst recommendations.

Valuation and benefits

This table compares the gross revenue, earnings per share (EPS), and valuation of CONMED and Helius Medical Technologies.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
CONMED $1.01 billion 3.37 $62.54 million $1.94 59.40
Helius Medical Technologies $520,000.00 11.05 -$18.13 million ($7.05) -0.21

CONMED has higher revenue and profit than Helius Medical Technologies. Helius Medical Technologies trades at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Analyst Notes

This is a breakdown of the current ratings of CONMED and Helius Medical Technologies, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
CONMED 0 1 3 0 2.75
Helius Medical Technologies 0 1 0 0 2.00

CONMED currently has a consensus price target of $161.67, suggesting a potential upside of 40.30%. Helius Medical Technologies has a consensus price target of $20.00, suggesting a potential upside of 1,221.09%. Given the higher possible upside of Helius Medical Technologies, analysts clearly believe that Helius Medical Technologies is more favorable than CONMED.


This table compares the net margins, return on equity, and return on assets of CONMED and Helius Medical Technologies.

Net margins Return on equity return on assets
CONMED 6.19% 13.20% 5.66%
Helius Medical Technologies -3,043.95% -232.55% -175.39%

Institutional and Insider Ownership

29.7% of Helius Medical Technologies shares are held by institutional investors. 1.1% of CONMED shares are held by company insiders. By comparison, 8.1% of the shares of Helius Medical Technologies are held by insiders of the company. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a stock will outperform the market over the long term.

Volatility and risk

CONMED has a beta of 1.53, suggesting its stock price is 53% more volatile than the S&P 500. In comparison, Helius Medical Technologies has a beta of 0.82, suggesting its stock price is 18% less volatile than the S&P 500.


CONMED beats Helius Medical Technologies on 10 out of 14 factors compared between the two stocks.

CONMED Company Profile (Get a rating)

CONMED Corporation, a medical technology company, develops, manufactures and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-in-One Soft Tissue Fixation System, Y-knot Suture Anchors and PopLok Knotless Suture Anchors, which provide unique clinical solutions for surgeons. orthopedists for soft tissue repair. injuries, as well as support products that allow surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgery and endomechanics products; and endoscopic technologies, including diagnostic and therapeutic products used in gastroenterology procedures and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products including ECG and EEG electrodes and defibrillation electrodes cardiac. The company markets its products directly to hospitals, surgical centers and other healthcare facilities, as well as through specialty medical distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Helius Medical Technologies Company Profile (Get a rating)

Helius Medical Technologies, Inc., a neurotechnology company, is focused on developing, licensing and acquiring noninvasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, the Wearable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short-term treatment for gait deficit due to symptoms of multiple sclerosis and balance deficit due to mild to moderate traumatic brain injury, so to be used in conjunction with supervised therapeutic exercises. The company is headquartered in Newtown, Pennsylvania.

Get news and reviews for CONMED Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for CONMED and related companies with’s FREE daily newsletter.

Comments are closed.